Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer
- 8 March 2021
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 6705-6713
Abstract
Ovarian cancer with miliary disease spread is an aggressive phenotype lacking targeted management strategies. We sought to determine whether adjuvant intraKeywords
This publication has 18 references indexed in Scilit:
- Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerJournal of Clinical Oncology, 2015
- A multicentric trial (Olympia–MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2013
- Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group studyGynecologic Oncology, 2013
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group StudyBritish Journal of Cancer, 2013
- Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer ChemotherapeuticsClinical Pharmacokinetics, 2012
- Aggressive and complex surgery for advanced ovarian cancer: An economic analysisGynecologic Oncology, 2009
- A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot StudyAnnals of Surgical Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatmentCancer Chemotherapy and Pharmacology, 1990